Aurobindo Pharma Stock

Aurobindo Pharma EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Aurobindo Pharma (AUROPHARMA.NS) as of Aug 16, 2026 is 66.17 B INR. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 58.77 B INR — a change of 12.60% (higher).

EBITDA

66.17 BINR

YoY

12.60%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Aurobindo Pharma is 2026 66.17 B INR. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Aurobindo Pharma was 2025 58.77 B INR. It decreases by 12.60% higher compared to the previous year.
Access this data via the Eulerpool API

Aurobindo Pharma Stock analysis

What does Aurobindo Pharma do? Aurobindo Pharma Ltd is a global pharmaceutical company based in India. It was founded in 1986 by P.V. Ramprasad Reddy, K. Nityananda Reddy, and Kambhampati Hari Babu. It has become one of the leading companies in the industry over the past 35 years. The company's business model is based on the production and distribution of generics, active pharmaceutical ingredients, and biosimilars. It operates in several divisions, covering a wide range of products. Aurobindo Pharma's main division is the manufacturing of generics, including both simple generics and complex products like biosimilars. The company also produces a variety of pharmaceutical ingredients used in industries such as pharmacy, cosmetics, and food. In addition, Aurobindo is involved in the production of biosimilars, which are biological drugs that have similar properties to existing biological products. These products have the potential to improve access to life-saving medications and generate significant cost savings. Aurobindo also manufactures products for the veterinary medicine industry, including antibiotics, antiparasitics, and vitamins. The company has also established a strong presence in the American market in recent years through acquisitions and offers a wide range of products. It has also expanded its presence in Europe, Asia, and Africa. In 2020, Aurobindo Pharma played a significant role in combating the COVID-19 pandemic by introducing several medications that can be used to treat the virus, such as hydroxychloroquine and azithromycin for mild to moderate cases. The company has earned a reputation as a leader in the generics and active pharmaceutical ingredient markets and aims to provide high-quality medications at affordable prices, making a positive contribution to global health improvement. Aurobindo Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Aurobindo Pharma stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Aurobindo Pharma is 66.17 B INR in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Aurobindo Pharma changed from 58.77 B INR to 66.17 B INR, representing a 12.60% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Aurobindo Pharma since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Aurobindo Pharma historically and in real time.

Access this data via the Eulerpool API

Income Statement — Aurobindo Pharma

All Key Metrics — Aurobindo Pharma